

Robert T Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3877404/publications.pdf>

Version: 2024-02-01

59
papers

4,568
citations

186265
28
h-index

138484
58
g-index

62
all docs

62
docs citations

62
times ranked

3878
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland. <i>New England Journal of Medicine</i> , 2004, 350, 896-903. | 27.0 | 810 |
| 2 | The Guillain-Barré Syndrome and the 1992-1993 and 1993-1994 Influenza Vaccines. <i>New England Journal of Medicine</i> , 1998, 339, 1797-1802. | 27.0 | 489 |
| 3 | The vaccine adverse event reporting system (VAERS). <i>Vaccine</i> , 1994, 12, 542-550. | 3.8 | 342 |
| 4 | Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 287-294. | 2.0 | 323 |
| 5 | Vaccinations and Risk of Central Nervous System Demyelinating Diseases in Adults. <i>Archives of Neurology</i> , 2003, 60, 504. | 4.5 | 233 |
| 6 | Population-based study of rotavirus vaccination and intussusception. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 410-416. | 2.0 | 210 |
| 7 | Vaccine adverse events: causal or coincidental?. <i>Lancet</i> , 1998, 351, 611-612. | 13.7 | 157 |
| 8 | Confounding in Studies of Adverse Reactions to Vaccines. <i>American Journal of Epidemiology</i> , 1992, 136, 121-135. | 3.4 | 152 |
| 9 | Vaccine risks: real, perceived and unknown. <i>Vaccine</i> , 1999, 17, S41-S46. | 3.8 | 139 |
| 10 | Active Surveillance of Vaccine Safety. <i>Epidemiology</i> , 2005, 16, 336-341. | 2.7 | 137 |
| 11 | The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). <i>Vaccine</i> , 2002, 21, 298-302. | 3.8 | 134 |
| 12 | Epidemiology of Autoimmune Reactions Induced by Vaccination. <i>Journal of Autoimmunity</i> , 2001, 16, 309-318. | 6.5 | 129 |
| 13 | Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After Measles-Mumps-Rubella Vaccine in the United States. <i>Pediatrics</i> , 2002, 110, e71-e71. | 2.1 | 108 |
| 14 | Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. <i>Vaccine</i> , 2020, 38, 4783-4791. | 3.8 | 102 |
| 15 | Vaccine Safety: Current and Future Challenges. <i>Pediatric Annals</i> , 1998, 27, 445-455. | 0.8 | 93 |
| 16 | Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. <i>MMWR Surveillance Summaries</i> , 2003, 52, 1-24. | 34.6 | 90 |
| 17 | Comparative Safety of Two Recombinant Hepatitis B Vaccines in Children. <i>Journal of Clinical Epidemiology</i> , 1998, 51, 503-510. | 5.0 | 62 |
| 18 | Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2015, 33, 62-72. | 3.8 | 56 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Outbreak of pyogenic abscesses after diphtheria and tetanus toxoids and pertussis vaccination. <i>Pediatric Infectious Disease Journal</i> , 1993, 12, 368-371. | 2.0 | 54 |
| 20 | Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2016, 34, 6597-6609. | 3.8 | 53 |
| 21 | Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2021, 39, 3081-3101. | 3.8 | 51 |
| 22 | The Brighton Collaboration: enhancing comparability of vaccine safety data. <i>Pharmacoepidemiology and Drug Safety</i> , 2003, 12, 335-340. | 1.9 | 50 |
| 23 | Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. <i>Vaccine</i> , 2009, 27, 2282-2288. | 3.8 | 48 |
| 24 | Enhancing vaccine safety capacity globally: A lifecycle perspective. <i>Vaccine</i> , 2015, 33, D46-D54. | 3.8 | 41 |
| 25 | Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. <i>Expert Review of Vaccines</i> , 2003, 2, 21-29. | 4.4 | 38 |
| 26 | Standardized case definitions of adverse events following immunization (AEFI). <i>Vaccine</i> , 2004, 22, 547-550. | 3.8 | 38 |
| 27 | The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. <i>Vaccine</i> , 2021, 39, 3067-3080. | 3.8 | 36 |
| 28 | Myocarditis: the unexpected return of smallpox vaccine adverse events. <i>Lancet</i> , The, 2003, 362, 1345-1346. | 13.7 | 32 |
| 29 | Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. <i>Vaccine</i> , 2016, 34, 6610-6616. | 3.8 | 32 |
| 30 | The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). <i>Vaccine</i> , 2015, 33, 73-75. | 3.8 | 26 |
| 31 | Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines. <i>Vaccine</i> , 2013, 31, 3623-3627. | 3.8 | 25 |
| 32 | Evaluation of vaccine safety after the events of 11 September 2001: role of cohort and case-control studies. <i>Vaccine</i> , 2004, 22, 2047-2053. | 3.8 | 21 |
| 33 | Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis. <i>Vaccine</i> , 2016, 34, 6617-6625. | 3.8 | 21 |
| 34 | Effect of point-of-care CD4 cell count results on linkage to care and antiretroviral initiation during a home-based HIV testing campaign: a non-blinded, cluster-randomised trial. <i>Lancet HIV</i> , the, 2017, 4, e393-e401. | 4.7 | 19 |
| 35 | Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines. <i>Vaccine</i> , 2019, 37, 5796-5802. | 3.8 | 18 |
| 36 | Template protocol for clinical trials investigating vaccines—Focus on safety elements. <i>Vaccine</i> , 2013, 31, 5602-5620. | 3.8 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | INDICATIONS FOR MEASLES-MUMPS-RUBELLA VACCINATION IN A CHILD WITH PRIOR THROMBOCYTOPENIA PURPURA. <i>Pediatric Infectious Disease Journal</i> , 1997, 16, 423-424. | 2.0 | 17 |
| 38 | Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil. <i>Vaccine</i> , 2013, 31, 950-954. | 3.8 | 16 |
| 39 | Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety. , 0, , 455-485. | | 15 |
| 40 | Vaccination and unexplained sudden death risk in Taiwanese infants. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 17-25. | 1.9 | 12 |
| 41 | A Process for Sentinel Case Review to Assess Causal Relationships between Smallpox Vaccination and Adverse Outcomes, 2003â€“2004. <i>Clinical Infectious Diseases</i> , 2008, 46, S271-S293. | 5.8 | 11 |
| 42 | Laboratory-based performance evaluation of PIMA CD4 + T-lymphocyte count point-of-care by lay-counselors in Kenya. <i>Journal of Immunological Methods</i> , 2017, 448, 44-50. | 1.4 | 11 |
| 43 | The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. <i>Vaccine</i> , 2020, 38, 5556-5561. | 3.8 | 9 |
| 44 | Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2022, 40, 5248-5262. | 3.8 | 9 |
| 45 | How to ensure we can track and trace global use of COVID-19 vaccines?. <i>Vaccine</i> , 2021, 39, 176-179. | 3.8 | 8 |
| 46 | Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services. <i>Clinical Infectious Diseases</i> , 2022, 75, S11-S17. | 5.8 | 8 |
| 47 | Preparing for the availability of a partially effective HIV vaccine: Some lessons from other licensed vaccines. <i>Vaccine</i> , 2011, 29, 6072-6078. | 3.8 | 7 |
| 48 | Enhancing Vaccine Safety Capacity Globally. <i>American Journal of Preventive Medicine</i> , 2015, 49, S364-S376. | 3.0 | 6 |
| 49 | The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines. <i>Vaccine</i> , 2020, 38, 6184-6189. | 3.8 | 6 |
| 50 | The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines. <i>Vaccine</i> , 2020, 38, 5734-5739. | 3.8 | 6 |
| 51 | Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. <i>Vaccine</i> , 2020, 38, 7702-7707. | 3.8 | 6 |
| 52 | Evolving pharmacovigilance requirements with novel vaccines and vaccine components. <i>BMJ Global Health</i> , 2021, 6, e003403. | 4.7 | 6 |
| 53 | Suitability of databases in the <scp>Asiaâ€™Pacific</scp> for collaborative monitoring of vaccine safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 843-857. | 1.9 | 5 |
| 54 | The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. <i>Vaccine</i> , 2020, 38, 7708-7715. | 3.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG). <i>Vaccine</i> , 2021, 39, 3050-3052. | 3.8 | 3 |
| 56 | A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). <i>Vaccine</i> , 2022, 40, 5275-5293. | 3.8 | 3 |
| 57 | Hospital-based collaboration for epidemiological investigation of vaccine safety: A potential solution for low and middle-income countries?. <i>Vaccine</i> , 2018, 36, 345-346. | 3.8 | 2 |
| 58 | A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus. <i>Vaccine</i> , 2022, 40, 5263-5274. | 3.8 | 2 |
| 59 | Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety. , 0, , 707-732. | | 0 |